Cargando…
Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation()
AIM: To assess clinical outcomes according to the immunosuppressive treatment administered to patients with severe SARS-CoV-2 pneumonia and moderate inflammation. METHODS: A retrospective observational cohort study involving 142 patients with severe COVID-19 pneumonia and moderate inflammation divid...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier España, S.L.U.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142037/ https://www.ncbi.nlm.nih.gov/pubmed/34056111 http://dx.doi.org/10.1016/j.medcle.2021.01.004 |
_version_ | 1783696494198521856 |
---|---|
author | Aomar-Millán, Ismael Francisco Salvatierra, Juan Torres-Parejo, Úrsula Nuñez-Nuñez, María Hernández-Quero, José Anguita-Santos, Francisco |
author_facet | Aomar-Millán, Ismael Francisco Salvatierra, Juan Torres-Parejo, Úrsula Nuñez-Nuñez, María Hernández-Quero, José Anguita-Santos, Francisco |
author_sort | Aomar-Millán, Ismael Francisco |
collection | PubMed |
description | AIM: To assess clinical outcomes according to the immunosuppressive treatment administered to patients with severe SARS-CoV-2 pneumonia and moderate inflammation. METHODS: A retrospective observational cohort study involving 142 patients with severe COVID-19 pneumonia and moderate inflammation divided into three treatment groups (pulses of methylprednisolone alone [group I], tocilizumab alone [group II] and methylprednisolone plus tocilizumab [group III]). The aim was to assess intergroups differences in the clinical course with a 60-day follow-up and related analytical factors. RESULTS: 14 patients (9,8%) died: 8 (10%) in group I and 6 (9,5%) in groups II and III. 15 (10,6%) were admitted to ICU: 2 (2,5%) from group I, 4 (28,5%) from group II and 9 (18,4%) from group III. The mean hospital stay was longer in group II and clinical outcome was not associated with treatment. CONCLUSIONS: Tocilizumab seems to be not associated with better clinical outcomes and should be reserved for clinical trial scenario, since its widespread use may result in higher rate of ICU admission and longer mean hospital stay without differences in mortality rate and potentially adverse events. |
format | Online Article Text |
id | pubmed-8142037 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier España, S.L.U. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81420372021-05-24 Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation() Aomar-Millán, Ismael Francisco Salvatierra, Juan Torres-Parejo, Úrsula Nuñez-Nuñez, María Hernández-Quero, José Anguita-Santos, Francisco Med Clin (Engl Ed) Brief Report AIM: To assess clinical outcomes according to the immunosuppressive treatment administered to patients with severe SARS-CoV-2 pneumonia and moderate inflammation. METHODS: A retrospective observational cohort study involving 142 patients with severe COVID-19 pneumonia and moderate inflammation divided into three treatment groups (pulses of methylprednisolone alone [group I], tocilizumab alone [group II] and methylprednisolone plus tocilizumab [group III]). The aim was to assess intergroups differences in the clinical course with a 60-day follow-up and related analytical factors. RESULTS: 14 patients (9,8%) died: 8 (10%) in group I and 6 (9,5%) in groups II and III. 15 (10,6%) were admitted to ICU: 2 (2,5%) from group I, 4 (28,5%) from group II and 9 (18,4%) from group III. The mean hospital stay was longer in group II and clinical outcome was not associated with treatment. CONCLUSIONS: Tocilizumab seems to be not associated with better clinical outcomes and should be reserved for clinical trial scenario, since its widespread use may result in higher rate of ICU admission and longer mean hospital stay without differences in mortality rate and potentially adverse events. Elsevier España, S.L.U. 2021-06-25 2021-05-24 /pmc/articles/PMC8142037/ /pubmed/34056111 http://dx.doi.org/10.1016/j.medcle.2021.01.004 Text en © 2021 Elsevier España, S.L.U. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Brief Report Aomar-Millán, Ismael Francisco Salvatierra, Juan Torres-Parejo, Úrsula Nuñez-Nuñez, María Hernández-Quero, José Anguita-Santos, Francisco Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation() |
title | Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation() |
title_full | Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation() |
title_fullStr | Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation() |
title_full_unstemmed | Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation() |
title_short | Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation() |
title_sort | glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe sars-cov-2 pneumonia and mild inflammation() |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142037/ https://www.ncbi.nlm.nih.gov/pubmed/34056111 http://dx.doi.org/10.1016/j.medcle.2021.01.004 |
work_keys_str_mv | AT aomarmillanismaelfrancisco glucocorticoidsaloneversustocilizumabaloneorglucocorticoidsplustocilizumabinpatientswithseveresarscov2pneumoniaandmildinflammation AT salvatierrajuan glucocorticoidsaloneversustocilizumabaloneorglucocorticoidsplustocilizumabinpatientswithseveresarscov2pneumoniaandmildinflammation AT torresparejoursula glucocorticoidsaloneversustocilizumabaloneorglucocorticoidsplustocilizumabinpatientswithseveresarscov2pneumoniaandmildinflammation AT nuneznunezmaria glucocorticoidsaloneversustocilizumabaloneorglucocorticoidsplustocilizumabinpatientswithseveresarscov2pneumoniaandmildinflammation AT hernandezquerojose glucocorticoidsaloneversustocilizumabaloneorglucocorticoidsplustocilizumabinpatientswithseveresarscov2pneumoniaandmildinflammation AT anguitasantosfrancisco glucocorticoidsaloneversustocilizumabaloneorglucocorticoidsplustocilizumabinpatientswithseveresarscov2pneumoniaandmildinflammation |